Market Cap 152.26B
Revenue (ttm) 63.63B
Net Income (ttm) 8.03B
EPS (ttm) N/A
PE Ratio 7.98
Forward PE 8.69
Profit Margin 12.62%
Debt to Equity Ratio 0.66
Volume 72,650,700
Avg Vol 49,734,617
Day's Range N/A - N/A
Shares Out 5.69B
Stochastic %K 64%
Beta 0.47
Analysts Sell
Price Target $28.43

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and tre...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
TalonKarrde
TalonKarrde Feb. 6 at 3:35 AM
$NWBO 🧭 The Tail They Learned to Trust — Two #KEYTRUDA Alumni and One Immune Architecture Linking #DCVax-L with $MRK, $PFE, $AMGN, $REGN, and $NWBO into a Converging #immunotherapy Operating System Arun Balakumaran and Kevin Duffy matter here for a forensic reason: they were trained inside the same KEYTRUDA franchise on complementary lanes, and exposed to the same constraint that still governs outcomes across tumors. PD-1 blockade became the defining franchise in cancer medicine, and both learned its boundary from different sides of the machine. Checkpoint blockade can amplify an immune response that already exists. It is unreliable at creating a new, durable repertoire from scratch. That limitation is the bridge to DCVax-L. Balakumaran is a physician-scientist who lived on the development side of KEYTRUDA hematology, where trial design, survival curves, and regulatory strategy are built. His later chapters track the durability toolbox: industrial execution, redirected T cells, engineered persistence, and escape physics that still defeat single-target systems. He is now Therapeutic Area Head for Heme Oncology at Pfizer, sitting inside a portfolio of downstream modules that become more coherent once an upstream instruction layer exists. Duffy lived on the scientific affairs side of the same franchise lane, where trials become medical reality: internal training, KOL networks, investigator-initiated studies, and field adoption. He joined NWBO from Merck in 2019 as Vice President, Medical Affairs and External Collaborations, stayed roughly nine months, returned briefly to Merck, and later moved into Regeneron’s oncology field medical lane. His orbit never leaves checkpoint biology and T cell-directed therapeutics, the terrain where dendritic instruction is not a nice-to-have but the missing upstream layer. One is trained to read durable curves and predictable failure modes. One is trained to judge whether the platform behind those curves is real and deployable. DCVax-L is the system that makes their paths legible. To keep the logic explicit, this narrative follows one thread: the KEYTRUDA constraint, instruction biology, the scaling lane, escape physics, the empirical tail, the University of Pennsylvania precedent and named investigators, the Pfizer plug-in stack as module compatibility, the coordination signal, and the manufacturing layer that determines whether any of it can exist outside boutique care. https://x.com/andrewcaravello/status/2019613805165089230?s=46
0 · Reply
Micheal_Pothead
Micheal_Pothead Feb. 6 at 2:35 AM
$PFE I’m getting Pfizer ads on Hulu lol
0 · Reply
blueblood12
blueblood12 Feb. 6 at 2:16 AM
$PFE this has been the works for a while $113M investment by $DJT
0 · Reply
zount82
zount82 Feb. 6 at 2:14 AM
$PFE Anyone have a link or screenshot of the Morgan Stanley note on Pfizer losing their patent case on Tafamadis?
0 · Reply
blueblood12
blueblood12 Feb. 6 at 1:29 AM
Trump pumping ozempic the great deal in the making $NVO $PFE $LLY $SPY
1 · Reply
Crypto9999
Crypto9999 Feb. 6 at 12:26 AM
$PFE Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans... The track back to ATH's $50++++🧲🧲🧲🧲
0 · Reply
Sjs360
Sjs360 Feb. 5 at 10:04 PM
$PFE $TTD $SMCI I am sooo good at losing money
1 · Reply
Sb2001
Sb2001 Feb. 5 at 9:55 PM
$PFE ok, that was officially crazy, but not unexpected in this name. What company made a killing selling 27 covered calls ?
0 · Reply
SeriouslyWhy
SeriouslyWhy Feb. 5 at 9:48 PM
$PFE geez 🙄
0 · Reply
_Crim_Jamer_
_Crim_Jamer_ Feb. 5 at 9:06 PM
$PFE yeesh not even one green day.
0 · Reply
Latest News on PFE
Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript

Feb 3, 2026, 3:00 PM EST - 2 days ago

Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript


Pfizer: Messy Q4 Earnings Mask An Improving Business

Feb 3, 2026, 2:02 PM EST - 2 days ago

Pfizer: Messy Q4 Earnings Mask An Improving Business


Silver Surges Over 15%; Pfizer Earnings Top Views

Feb 3, 2026, 12:00 PM EST - 2 days ago

Silver Surges Over 15%; Pfizer Earnings Top Views


Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand

Feb 3, 2026, 7:21 AM EST - 2 days ago

Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand


Pfizer: Buyer Beware, The Risk Outweighs The Reward

Jan 30, 2026, 10:31 AM EST - 6 days ago

Pfizer: Buyer Beware, The Risk Outweighs The Reward


Pfizer: A High-Yield Pharma At A Turning Point

Jan 29, 2026, 9:00 AM EST - 7 days ago

Pfizer: A High-Yield Pharma At A Turning Point


Pfizer vs. Merck Stock And JNJ

Jan 27, 2026, 7:40 AM EST - 9 days ago

Pfizer vs. Merck Stock And JNJ


Pfizer: Expect Another Double Beating For Q1 (Earnings Preview)

Jan 23, 2026, 10:33 AM EST - 13 days ago

Pfizer: Expect Another Double Beating For Q1 (Earnings Preview)


Pfizer CEO Albert Bourla: U.S. drug prices are coming down

Jan 20, 2026, 12:34 PM EST - 16 days ago

Pfizer CEO Albert Bourla: U.S. drug prices are coming down


Japan's Shionogi boosts ViiV stake to 21.7% as Pfizer exits

Jan 20, 2026, 2:19 AM EST - 16 days ago

Japan's Shionogi boosts ViiV stake to 21.7% as Pfizer exits


MoneyShow's Best Investment Ideas For 2026: Part 7

Jan 19, 2026, 2:20 PM EST - 17 days ago

MoneyShow's Best Investment Ideas For 2026: Part 7

PLD PLG PM QUIK RCAT


Pfizer: Rebound Has Just Started

Jan 16, 2026, 1:08 PM EST - 20 days ago

Pfizer: Rebound Has Just Started


Pfizer: The Most Intriguing Value Play Of 2026

Jan 15, 2026, 8:58 AM EST - 21 days ago

Pfizer: The Most Intriguing Value Play Of 2026


Pfizer's Patent Cliff, Rising Debt, And The Fight To Stay A Buy

Jan 13, 2026, 6:11 AM EST - 23 days ago

Pfizer's Patent Cliff, Rising Debt, And The Fight To Stay A Buy


Quant Q&A With Steven Cress

Jan 7, 2026, 7:00 AM EST - 4 weeks ago

Quant Q&A With Steven Cress

CLS CRDO ET FIX MRK


Pfizer 2026: The Reset Year

Jan 2, 2026, 2:52 PM EST - 4 weeks ago

Pfizer 2026: The Reset Year


TalonKarrde
TalonKarrde Feb. 6 at 3:35 AM
$NWBO 🧭 The Tail They Learned to Trust — Two #KEYTRUDA Alumni and One Immune Architecture Linking #DCVax-L with $MRK, $PFE, $AMGN, $REGN, and $NWBO into a Converging #immunotherapy Operating System Arun Balakumaran and Kevin Duffy matter here for a forensic reason: they were trained inside the same KEYTRUDA franchise on complementary lanes, and exposed to the same constraint that still governs outcomes across tumors. PD-1 blockade became the defining franchise in cancer medicine, and both learned its boundary from different sides of the machine. Checkpoint blockade can amplify an immune response that already exists. It is unreliable at creating a new, durable repertoire from scratch. That limitation is the bridge to DCVax-L. Balakumaran is a physician-scientist who lived on the development side of KEYTRUDA hematology, where trial design, survival curves, and regulatory strategy are built. His later chapters track the durability toolbox: industrial execution, redirected T cells, engineered persistence, and escape physics that still defeat single-target systems. He is now Therapeutic Area Head for Heme Oncology at Pfizer, sitting inside a portfolio of downstream modules that become more coherent once an upstream instruction layer exists. Duffy lived on the scientific affairs side of the same franchise lane, where trials become medical reality: internal training, KOL networks, investigator-initiated studies, and field adoption. He joined NWBO from Merck in 2019 as Vice President, Medical Affairs and External Collaborations, stayed roughly nine months, returned briefly to Merck, and later moved into Regeneron’s oncology field medical lane. His orbit never leaves checkpoint biology and T cell-directed therapeutics, the terrain where dendritic instruction is not a nice-to-have but the missing upstream layer. One is trained to read durable curves and predictable failure modes. One is trained to judge whether the platform behind those curves is real and deployable. DCVax-L is the system that makes their paths legible. To keep the logic explicit, this narrative follows one thread: the KEYTRUDA constraint, instruction biology, the scaling lane, escape physics, the empirical tail, the University of Pennsylvania precedent and named investigators, the Pfizer plug-in stack as module compatibility, the coordination signal, and the manufacturing layer that determines whether any of it can exist outside boutique care. https://x.com/andrewcaravello/status/2019613805165089230?s=46
0 · Reply
Micheal_Pothead
Micheal_Pothead Feb. 6 at 2:35 AM
$PFE I’m getting Pfizer ads on Hulu lol
0 · Reply
blueblood12
blueblood12 Feb. 6 at 2:16 AM
$PFE this has been the works for a while $113M investment by $DJT
0 · Reply
zount82
zount82 Feb. 6 at 2:14 AM
$PFE Anyone have a link or screenshot of the Morgan Stanley note on Pfizer losing their patent case on Tafamadis?
0 · Reply
blueblood12
blueblood12 Feb. 6 at 1:29 AM
Trump pumping ozempic the great deal in the making $NVO $PFE $LLY $SPY
1 · Reply
Crypto9999
Crypto9999 Feb. 6 at 12:26 AM
$PFE Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans... The track back to ATH's $50++++🧲🧲🧲🧲
0 · Reply
Sjs360
Sjs360 Feb. 5 at 10:04 PM
$PFE $TTD $SMCI I am sooo good at losing money
1 · Reply
Sb2001
Sb2001 Feb. 5 at 9:55 PM
$PFE ok, that was officially crazy, but not unexpected in this name. What company made a killing selling 27 covered calls ?
0 · Reply
SeriouslyWhy
SeriouslyWhy Feb. 5 at 9:48 PM
$PFE geez 🙄
0 · Reply
_Crim_Jamer_
_Crim_Jamer_ Feb. 5 at 9:06 PM
$PFE yeesh not even one green day.
0 · Reply
Micheal_Pothead
Micheal_Pothead Feb. 5 at 8:46 PM
$PFE guess we became a crypto company in the last 2 hours
2 · Reply
Micheal_Pothead
Micheal_Pothead Feb. 5 at 8:39 PM
$PFE wow what a dog shit daily candle we are printing
0 · Reply
taxplanr
taxplanr Feb. 5 at 8:31 PM
Tennessee legislator intorduces MRNA Bioweapons Prohibition Act $BNTX $MRNA $PFE $MRK https://www.josephsansone.com/p/breaking-tennessee-state-senator?utm_source=cross-post&publication_id=1021940&post_id=186980988&utm_campaign=956088&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
Micheal_Pothead
Micheal_Pothead Feb. 5 at 8:16 PM
$PFE well that’s disappointing
0 · Reply
edlu77
edlu77 Feb. 5 at 8:14 PM
$PFE Closing red
0 · Reply
Jessicaparks111
Jessicaparks111 Feb. 5 at 7:56 PM
$PFE Bourla tears
0 · Reply
free2dream
free2dream Feb. 5 at 7:47 PM
$SRPT I might have to sell my $PFE to buy more down here.
0 · Reply
FRAGMENTS
FRAGMENTS Feb. 5 at 7:16 PM
0 · Reply
EmbraceVolatility
EmbraceVolatility Feb. 5 at 6:53 PM
$PFE Glad I didn't sell for NVO. Slow mover but very bullish. That said, expect a test of around $26 at some point. $28+ this year minimum.
1 · Reply
JBS_84
JBS_84 Feb. 5 at 6:46 PM
$PFE I don't see anything other than normal up and down within the channel. 26 might be new support or 25.75. I think we see that again soon. If it breaks significantly above 27.5 I'll revisit and hope for 30 but I'd certainly not expect that. This warrants extreme caution at this 27 area.
0 · Reply
_Crim_Jamer_
_Crim_Jamer_ Feb. 5 at 6:42 PM
$PFE let's go!
0 · Reply
STOCKPICKERTRADER
STOCKPICKERTRADER Feb. 5 at 6:39 PM
$PFE intraday bullish cup/handle with push above that 27.19 bringing 27.4x area and suspect pressing above that 27.5x for option purge through tomorrow likely
1 · Reply